AQR Arbitrage’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History

AQR Arbitrage’s Portfolio NRXPW Stock Details NRXPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-54,256	Closed	-$255K	–	1244
2021 Q3	$255K	Sell	54,256 -45,744	-46%	-$282K	0.01%	712
2021 Q2	$356K	Hold	100,000	–	–	0.01%	695
2021 Q1	$971K	Hold	100,000	–	–	0.03%	408
2020 Q4	$470K	Hold	100,000	–	–	0.02%	688
2020 Q3	$26K	Hold	100,000	–	–	﹤0.01%	559
2020 Q2	$45K	Hold	100,000	–	–	﹤0.01%	508
2020 Q1	$6K	Hold	100,000	–	–	﹤0.01%	563
2019 Q4	$17K	Hold	100,000	–	–	﹤0.01%	456
2019 Q3	$17K	Hold	100,000	–	–	﹤0.01%	446
2019 Q2	$24K	Hold	100,000	–	–	﹤0.01%	488
2019 Q1	$18K	Hold	100,000	–	–	﹤0.01%	523
2018 Q4	$38K	Hold	100,000	–	–	﹤0.01%	561
2018 Q3	$45K	Hold	100,000	–	–	﹤0.01%	476
2018 Q2	$38K	Hold	100,000	–	–	﹤0.01%	440
2018 Q1	$45K	Hold	100,000	–	–	﹤0.01%	389
2017 Q4	$40K	Buy	+100,000	New	+$38.1K	﹤0.01%	364

Other funds holding NRXPW

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AQR Arbitrage's NRXPW Position: Q4 2021 in Review

AQR Arbitrage sold out of NRX Pharmaceuticals Warrant (NRXPW) in Q4 2021, closing a stake of 54,256 shares — an estimated $255K sold.

AQR Arbitrage first reported a position in NRXPW in Q4 2017 and held it in 16 quarters. The position peaked at $971K in Q1 2021. 4 funds tracked by Wall St. Rank hold NRXPW as of Q4 2021.

AQR Arbitrage reported no remaining NRX Pharmaceuticals Warrant position as of Q4 2021 after selling out during the quarter.
AQR Arbitrage sold 54,256 NRX Pharmaceuticals Warrant shares in Q4 2021, an estimated $255K.
AQR Arbitrage first reported a position in NRX Pharmaceuticals Warrant in Q4 2017 and held it in 16 quarters.
AQR Arbitrage's NRX Pharmaceuticals Warrant position peaked at $971K in Q1 2021.
4 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q4 2021.

Based on AQR Arbitrage's 13F filing for Q4 2021, filed 14 Feb 2022.